Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Claude Cormier who wrote (11915)	1/22/2003 2:03:05 AM
From: axial	Read Replies (1) \| Respond to of 14101

"Short term, assuming HC and FDA, I will be happy with $4-$5" That is the reality of a bear." Yes, and it's looking more bearish every day. I don't disagree with you. The kicker in this stock is not Pennsaid - it's WF10. If WF10 shows real potential, then the effect on the $4-$5 price will be additive - even in this bear market. I believe the evidence supports an inference that efficacy has been established. The big worry was that the data from the Phase 3 trials had been compromised by the CRO. In the next few months, if the news is that WF10 has had a beneficial effect as salvage therapy - even in patients using HAART - then this stock will move. DMX is about WF10; not Pennsaid. But who knows? The good news is that it won't take long to find out, one way or the other. If the FDA and DMX go into pre-NDA meetings, then we can expect some word around 90 days later (or thereabouts), maybe at some kind of professional association meeting. Regards, Jim